Life Sciences Partners BV (LSP) of the Netherlands has raised $600 million for its sixth life science fund, enabling it to invest in 15 to 18 predominantly European private companies developing new medicines and medical technologies. LSP 6 is one of the largest funds in Europe dedicated to this sector. Announcing the fund’s close on 10 March, LSP said that it was able to attract funds from a diverse group of investors including pension funds, insurance companies, wealth managers, government funds and family offices.
